Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Trading Cabana -- Ignore unavailable to you. Want to Upgrade?

To: RockyBalboa who wrote (3683)	6/30/2008 1:31:33 PM
From: The Reaper	Read Replies (1) \| Respond to of 6370

Mid... I know you love to research these kind of plays. PACW PCBC 2 California banks that could be GTZ. PACW for instance has almost 80% of its loan portfolio in commercial loans and commercial real estate CONSTRUCTION loans. Announced writeoffs have been minimal to date but they are scheduled to report 8/11. PCBC is involved in ground zero for bad residential real estate loans east of Los Angeles in "The Inland Empire".

To: RockyBalboa who wrote (3683)	6/30/2008 3:51:36 PM
From: RockyBalboa	Read Replies (1) \| Respond to of 6370

THis is what analysts say: Citi analyst Lucy Lu said she thinks the company's core molecular diagnostics business is worth $50 per share. She maintained a "Hold" rating on the stock. Cowen analyst Ian Sanderson said the stock could trade in the low $40-range, and Michael Yee of RBC Capital Markets predicted a "near-term valuation floor" of $37 per share. Lu had said there was less than a 10 percent chance the trial would be successful, and Sanderson was only slightly more optimistic...